Candel Therapeutics, Inc.
CADL
$12.17
-$0.43-3.41%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.64% | 34.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 64.25% | 3.42% | |||
| Operating Income | -64.25% | -3.42% | |||
| Income Before Tax | -339.06% | 69.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -339.06% | 69.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -339.06% | 69.96% | |||
| EBIT | -64.25% | -3.42% | |||
| EBITDA | -64.70% | -3.55% | |||
| EPS Basic | -269.32% | 73.55% | |||
| Normalized Basic EPS | -269.37% | 73.55% | |||
| EPS Diluted | -269.32% | 73.55% | |||
| Normalized Diluted EPS | -269.37% | 73.55% | |||
| Average Basic Shares Outstanding | 18.87% | 13.60% | |||
| Average Diluted Shares Outstanding | 18.87% | 13.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||